CYSLTR1 and cancer: Despite the limited molecular changes observed by Western blotting, we proceeded to the MUM xenograft model, as the CysLT1 antagonists reduce proliferation and cellular metabolism of OMM2.5 cells in vitro and modulate the cancer secretome of patient UM explants ex vivo.